What Lipid-lowering Therapy Is Best for Huge Low & Moderate Risk Population?
[Speaker] Jae-Hyeong Park/Korea Univ., Korea
How Much Would Be Cost Effectiveness Important for New Lipid Lowering Agents?
[Speaker] Hyun-Jae Kang/Seoul National Univ., Korea
Updated Evidence on Lipid Targets in Korean Studies
[Speaker] Byeong-Keuk Kim/Yonsei Univ., Korea
Discussion